Heterocyclic Sulfonamide Kv1.3 Inhibitors With Selective Channel Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of the potassium channel Kv1.3 to treat autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal, and metabolic mediated diseases.
Innovation Solution
Development of heterocyclic sulfonamide derivatives that can modulate potassium channels, specifically targeting Kv1.3, to provide therapeutic benefits for various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional potassium channel inhibitors are used, then therapeutic effects are achieved, but slow off-rate limits treatment effectiveness
Solution Approach 1:
The patent modifies the chemical structure parameters of potassium channel inhibitors by introducing specific heterocyclic sulfonamide groups and substituent patterns, which fundamentally changes the binding kinetics to achieve slow off-rate characteristics while maintaining therapeutic effectiveness
2Reliability
If Kv1.3 inhibition is achieved, then T-cell function is modulated for autoimmune disease treatment, but selectivity among different potassium channels may be compromised
Solution Approach 1:
The patent introduces specific local structural features at particular positions of the molecule (such as heterocyclic rings at R1, R2, R3 positions and specific sulfonamide configurations) that create localized interactions with Kv1.3 channel residues, enhancing selectivity for this specific channel while maintaining T-cell modulation efficacy
Data Source
AI summary
The invention relates to heterocyclic sulfonamide derivatives and their use in the treatment and prophylaxis of autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal and metabolic mediated diseases, and to compositions containing said derivatives and processes for their preparation.